SEL 24

Drug Profile

SEL 24

Alternative Names: MEN-1703; SEL24; SEL24 program; SEL24-1; SEL24-B489

Latest Information Update: 07 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Selvita
  • Developer Selvita; Theradex
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Proto oncogene proteins c pim 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia
  • Preclinical Lymphoma

Most Recent Events

  • 20 Dec 2017 SEL 24 is still in phase I/II trial for Acute myeloid leukaemia in USA
  • 20 Dec 2017 Selvita reinitiates a phase I/II trial in Acute myeloid leukaemia in USA (PO) (NCT03008187)
  • 20 Oct 2017 Selvita suspends patient enrolment in a phase I/II trial in Acute myeloid leukaemia in USA due to clinical hold (NCT03008187)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top